148 Characterizing cancer’s dark matter, short-lived proteins, and defective ribosomal products, presented by cancer and contained in the DPV-001 cancer vaccine
Biomarkers, Immune Monitoring and Novel Technologies
148 Characterizing cancer’s dark matter, short-lived proteins, and defective ribosomal products, presented by cancer and contained in the DPV-001 cancer vaccine
PDF